ANI Pharmaceuticals
ANIP
134 hedge funds and large institutions have $241M invested in ANI Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 26 closing their positions.
2% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 43
3% less call options, than puts
Call options by funds: $2.02M | Put options by funds: $2.08M
4% less funds holding
Funds holding: 140 → 134 (-6)
5.28% less ownership
Funds ownership: 65.84% → 60.56% (-5.3%)
23% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 26
26% less capital invested
Capital invested by funds: $325M → $241M (-$83.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$10.6M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.28M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.12M |
| 4 |
Morgan Stanley
New York
|
+$4.1M |
| 5 |
BlackRock
New York
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$17.4M |
| 2 |
First Manhattan
New York
|
-$11M |
| 3 |
HRCM
Hawk Ridge Capital Management
Los Angeles,
California
|
-$8.01M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$6.79M |
| 5 |
Renaissance Technologies
New York
|
-$3.19M |
ANIP Hedge Fund Activity: Q2 2020 in Review
134 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2020, worth a combined $241M — down 26% from $325M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ANIP and 20 opened new positions — a net loss of 6 holders — while 43 trimmed existing stakes and 42 added.
The largest buyer was Thompson Siegel & Walmsley, adding an estimated $10.6M. The largest seller was Mangrove Partners, exiting entirely with an estimated $17.4M sold.
- 134 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2020, down from 140 in Q1 2020.
- Funds reported $241M of ANI Pharmaceuticals stock for Q2 2020, down 26% quarter-over-quarter.
- 20 funds opened new ANI Pharmaceuticals positions in Q2 2020 and 26 closed out, a net change of -6 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2020 was Thompson Siegel & Walmsley, an estimated $10.6M added.
- The largest ANI Pharmaceuticals seller in Q2 2020 was Mangrove Partners, an estimated $17.4M sold.
Based on aggregated 13F filings for Q2 2020.